FRAZER, Pa. (AP) — Cephalon Inc. said Monday it hopes to ask the Food and Drug Administration to approve Nuvigil as a treatment for jet lag by the third quarter. The drug is already approved to treat several sleep disorders and is an updated version of Provigil, which also treats sleep disorders. Cephalon said Nuvigil met its goal in a late-stage study focusing on excessive sleepiness associated with jet lag. The company is also studying Nuvigil as a potential treatment for bipolar disorder.